Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MVC-COV1901
- Development stage
- Phase 4
- Lead developer
- Medigen Vaccine Biologics
- Modality
- Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
MVC-COV1901 is a protein subunit COVID-19 vaccine developed by Medigen Vaccine Biologics and Dynavax Technologies. It contains a recombinant prefusion spike protein (S-2P) of SARS-CoV-2, produced in Chinese hamster ovary cells, and is adjuvanted with CpG 1018 (a toll-like receptor 9 agonist) and aluminum hydroxide. The mechanism of action involves stimulating the immune system to produce neutralizing antibodies against the SARS-CoV-2 spike protein, thereby providing immunity against COVID-19[1][3][4][5][7][8]. The vaccine has been authorized for emergency use or approved in several countries including Taiwan, Paraguay, Eswatini, and Somaliland[4]. Clinical trials have demonstrated favorable safety and immunogenicity profiles.
- Brand names
- Medigen COVID-19 vaccineMVC COVID-19 vaccine
- Other names
- Adjuvanted coronavirus vaccine
02
Targets
TLR9 (Toll-like receptor 9)SARS-CoV-2 spike
Beyond the preview
Go deeper on MVC-COV1901.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MVC-COV1901.